A single-center non-blinded randomized clinical trial to assess the safety and effectiveness of PhR160 spray in the treatment of COVID-19 pneumonia
NOPR - NISCAIR Online Periodicals Repository
View Archive InfoField | Value | |
Title |
A single-center non-blinded randomized clinical trial to assess the safety and effectiveness of PhR160 spray in the treatment of COVID-19 pneumonia
|
|
Creator |
Roshandel, H R Sheikh
Mirkazemi, R Ahmadabadi, H R Memarzadeh, M R Zahedifard, N Saffari, M Jazani, M Rahmani, M Hosseini, M Raei, M Sharifi, AR Ghadimi, F Ameli, P Valinejad, M Mohtashami, R |
|
Subject |
COVID-19
Hospitalized patients Iranian Traditional Medicine Pinen-Hydronoplacton-Ribonucleic acid (PHR160) |
|
Description |
7-16
COVID-19 is an emerging pandemic that caused a very widespread infection with more than 1000000 cases in Iran within a year. The main cause of mortality among patients with COVID-19 is pulmonary failure. In Iranian Traditional Medicine, essences have been used for curing pulmonary diseases. Pinen-Hydronoplacton-Ribonucleic acid (PHR) is an inhaler spray made of seven different plants, which all are used by humans and have desirable pharmacological features for treating pulmonary symptoms of COVID-19 patients. This study was conducted to assess the safety and effectiveness of PHR160 spray in improving pulmonary symptoms of COVID-19 patients. This was a single-centre, non-blinded randomized clinical trial with two parallel groups in two different wards of Baqiyatallah hospital, Tehran, Iran. Participants were 63 male patients diagnosed with COVID-19 pneumonia, divided into 2 groups of 32 in the intervention group and 31 in the control group. The intervention group received 5 days of PHR160 spray, 10 puffs each day, 300 micrograms in each puff in addition to the routine treatment. Oxygen saturation was measured by a pulse oximeter, every six hours and recorded daily. This study showed that administration of PhR 160 in patients of COVID-19 was safe, and it significantly increased the arterial oxygen saturation percentage in COVID-19 patients. In addition, it decreased hospitalization duration, dyspnea score, and cough score significantly in the patients. The statistical modelling test, with adjusting the age and respiratory rate for baseline and 4 days of the intervention, shows that the oxygen saturation percentage mean was significantly more in the intervention group by 5.14 units (p |
|
Date |
2022-02-15T10:22:03Z
2022-02-15T10:22:03Z 2022-01 |
|
Type |
Article
|
|
Identifier |
0975-1068 (Online); 0972-5938 (Print)
http://nopr.niscair.res.in/handle/123456789/59180 |
|
Language |
en
|
|
Relation |
Int. Cl.22: A61K 9/72, A61K 31/00, A61K 36/00, A61K 45/00
|
|
Publisher |
CSIR-NIScPR
|
|
Source |
IJTK Vol.21(1) [January 2022]
|
|